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SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet
Needs, and Therapeutic Prospects
Carolyn S. P. Lam, MBBS, PhD; Chanchal Chandramouli, PhD; Vineeta Ahooja, MD, FACC, FASE; Subodh Verma, MD
H eart failure (HF) is a growing public health issue. Asmany as 1 in 5 people are expected to develop HF
during their lifetime,1 with an estimated 63 million people
affected worldwide.2 In 2012 HF was responsible for an
estimated health expenditure of $31 billion USD, a figure
anticipated to see an increase of 127% by 2030.3 The
increasing burden of HF on health care is primarily due to an
aging population, as evidenced by the predominance of HF as
a cause of hospitalization in individuals aged over 65 years.4
HF comprises an array of patients categorized by their
symptoms and ejection fraction (EF), including those with
reduced EF (EF<40%; HFrEF), midrange EF (EF between 40%
and 49%), and preserved EF (EF>50%; HFpEF).5 Recent trends
indicate that the prevalence of HFpEF is increasing relative to
HFrEF, with estimates suggesting that 65% of patients with HF
will have an EF>40% by 2020.4 Here, we review the current
unmet needs in the management of HF and discuss how these
needs may be addressed, focusing on the potential role of
sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
Substantial Unmet Needs in HF
Urgent Need for Prevention of HF in Individuals at
Risk, as Well as Early Recognition to Facilitate
Treatment Before Hospitalization
The importance of prevention of symptomatic HF is high-
lighted in current international HF guidelines,5,6 where the
progressive nature of HF, from preclinical to clinical stages, is
emphasized. Recognition of individuals at risk and the
presence of preclinical cardiac structural/functional HF
precursors are critical, because starting treatment at the
preclinical stage may prevent HF progression and improve
outcomes.7-9 Current US guidelines even recommend the use
of biomarker screening to identify patients at increased risk of
HF and, accordingly, adoption of preventative interventions.6
Even with symptomatic disease, major barriers to early
diagnosis and treatment of HF remain, such as poor awareness
of the disease among the general population10-13 and suboptimal
diagnosisbynonspecialist healthcarepractitioners,whomayhave
limited access to diagnostic tools such as echocardiography.14,15
This is of particular concern in view of the variable clinical
presentation of HF,16 as well as the overlap of symptoms (eg,
shortness of breath, exercise intolerance) of the condition with
common comorbidities, such as chronic obstructive pulmonary
disease, chronic kidney disease (CKD), anemia, and diabetes
mellitus.17-19Delay indiagnosisofHF isassociatedwithprolonged
time to treatment and increased length of hospital stay and
mortality.20,21 As patient hospitalization is associated with an
increased riskofmortality, early diagnosis is imperative.22Studies
indicate that patientshospitalized forHFhave a10%mortality rate
at30 dayspostdischarge23andthatthemortalityrateat1 yearfor
patients admitted to a hospital is 20%.24 Furthermore, the
readmission rate for HF at 6 months is 50%,25,26 and the risk of
mortality increases with each hospitalization.13
Established Treatments for HFrEF Are Associated
With Reduced Mortality
Although established treatments for HFrEF are associated
with reduced mortality, these patients continue to have a poor
prognosis, with many patients not receiving recommended
doses of treatment. Neurohormonal antagonists (angiotensin-
converting enzyme [ACE] inhibitors/angiotensin recep-
tor blockers [ARBs], b-blockers, and mineralocorticoid
receptor antagonists [MRA]) have been shown to reduce risk
of mortality in patients with HFrEF.27-29 In addition, the
PARADIGM-HF (Prospective Comparison of ARNI [angiotensin
receptor–neprilysin inhibitor] with ACEI [angiotensin-
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converting-enzyme inhibitor] to Determine Impact on Global
Mortality and Morbidity in Heart Failure) trial showed benefit
with ARNI, valsartan/sacubitril.30 Consequently, both Euro-
pean5 and US6 guidelines make the strongest recommenda-
tion for use of these neurohormonal agents, up-titrated to
optimal doses shown to be beneficial in clinical trials, to treat
appropriate patients with HFrEF.
Despite these guideline-recommended treatment options,
mortality for patients with HFrEF remains high,31 with recent US
registry data showing extremely poor 5-yearmortality (75%) and
hospital readmission (82%) rates.32 A critical challenge in the
management of HFrEF pertains to the large proportion of
patients who do not receive guideline-directed doses of
treatment. A prospective European study found that of 2100
patients with HFrEF from 11 countries, only 22% were success-
fully up-titratedovera3-monthperiod to the recommendeddose
ofACE inhibitors/ARBs, andonly12% to the recommendeddose
of b-blockers.33 The same study showed that patients with
HFrEF treated with less than 50% of the recommended dose of
ACE inhibitors/ARBs and b-blockers had a greater risk of death
and/or hospitalization for HF (hHF) than those reaching
maximum dose.33 Moreover, in the prospective multinational
ASIAN-HF (Asian Sudden Cardiac Death in Heart Failure)
registry, only 17% of patients received recommended doses of
ACE inhibitors or ARBs, and 13% for b-blockers.34 It is likely that
failure to achieve recommended dosing is partly attributable to
the length of time required to up-titrate to maximum dose, with
patients less likely to adhere to lengthy treatment processes
without benefiting from immediate clinical improvements, as
well as adverse events associated with current therapies (eg,
hypotension, worsening of renal function, and hyperkalemia).
Considering the significant residual risk associated with
HFrEF, there is an unmet need for disease-modifying therapies
that have an immediate impact on patient well-being without
dose-limiting side effects. At the same time, optimizing
treatment of HFrEF with existing therapies remains a key
therapeutic goal. Initiatives that support implementation of
best practice (eg, installation of in- and outpatient protocols
within practices, ensuring that guidelines are readily available
to all healthcare practitioners) may be valuable in facilitating
appropriate management of HFrEF.
No Therapy Has Been Shown to Convincingly
Reduce Mortality in HFpEF
Several established treatments for HFrEF have shown no
efficacy in trials of HFpEF, with no benefit demonstrated in the
CHARM-Preserved (Candesartan in Heart Failure: Assessment
of Reduction in Mortality and Morbidity; candesartan),35 PEP-
CHF (Perindopril for Elderly People with Chronic Heart Failure;
perindopril),36 I-PRESERVE (Irbesartan in Patients with Heart
Failure and Preserved Ejection Fraction; irbesartan),37 or
TOPCAT (Treatment of PreservedCardiac FunctionHeart Failure
with an Aldosterone Antagonist; spironolactone) trials.38 Con-
sequently, current European Society of Cardiology guidelines
continue to state that “no treatment has yet been shown,
convincingly, to reduce morbidity or mortality in patients with
HFpEF,” with the only class I recommendations being diuretics
for symptom control and treatment of comorbidities.5 The
American College of Cardiology/American Heart Association
guidelines similarly emphasize diuretics with a class I recom-
mendation to relieve the symptoms of HF, with the only other
class I recommendation being control of blood pressure. The
American guidelines also recommend management of atrial
fibrillation, addressing any myocardial ischemia with coronary
revascularization, and use of other guideline-recommended
therapies for comorbid conditions. Theseguidelinesalso include
a new class IIb recommendation for consideration of a miner-
alocorticoid receptor antagonist in appropriately selected
patients with symptomatic HFpEF, particularly those with
elevated natriuretic peptide levels, with close monitoring of
potassium levels and renal function.6 This is based on a post hoc
analysis of the TOPCAT trial, which showed efficacy of spirono-
lactone inpatientswithHFpEF in theAmericasbutnot inRussia/
Georgia.39
Cardiorenal Syndrome
The kidney and heart are inextricably linked, with acute or
chronic disorder of 1 organ system capable of damaging the
other; an interplay often referred to as cardiorenal syndrome.40
Studies have indicated that between 20% and 67% of patients
with HF have CKD.41 Patients with both HF and renal
insufficiency have 25% to 30% increased risk of mortality
compared with patients with HF alone.42 The pathophysiology
of renal disease in HF is complex: HF can lead to CKD through
increased venous pressure and low cardiac output resulting in
renal hypoperfusion, inflammation, and sympathetic activation.
Conversely, kidney dysfunction may worsen HF through
increased sodium and fluid retention, accelerated atheroscle-
rosis, inflammation, anemia, uremic toxins, and neurohormonal
activation.43 The progression of renal impairment in cardiorenal
syndrome is often difficult to predict, making its management
challenging. For instance, acute increases in serum creatinine
and cystatin C of 0.3 mg/dL each may be prognostic for
acute kidney injury and increased risk of hHF or death.44
However, transient worsening of renal functionwith appropriate
neurohormonal blockade and/or diuresis, together with car-
diovascular improvement, may not affect patient outcomes
postdischarge.44 Most importantly, the presence of significant
concomitant renal dysfunction severely limits the use of proven
HF medications, such as ACE inhibitors, ARBs, MRAs, and
ARNIs. In the absence of evidence-based therapies capable of
both renal and cardiovascular protection, outcomes for patients
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with cardiorenal syndrome may continue to be poor. Figure 1
summarizes the key unmet needs in HF.
Emerging Evidence Suggests SGLT-2
Inhibitors May Be Effective in Prevention of
HF in Patients With Diabetes Mellitus
Diabetesmellitus isan independent risk factor forHF,45withstudies
showing that subclinical atherosclerotic and nonatherosclerotic
myocardial damage occurs early in the natural history of diabetes
mellitus,oftenbeforediagnosisof thecondition.46SGLT-2 inhibitors
are approved for themanagement of type 2 diabetesmellitus (T2D)
and have recently been investigated in several large, placebo-
controlled trials for cardiovascular safety as well as efficacy in
patients with T2D.
Cardiovascular Outcomes Trials of SGLT-2
Inhibitors in Patients With T2D
EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus Patients) was the first
cardiovascular outcomes trial (CVOT) to investigate the effects
of SGLT-2 inhibition with empagliflozin on cardiovascular
outcomes in T2D.47 In patients with T2D and established
atherosclerotic disease (N=7020), empagliflozin met an
exploratory end point of statistically significant reduction in
hHF versus placebo.47 An absolute risk reduction (ARR) of 1.4%
and relative risk reduction of 35% in hHF was observed in the
empagliflozin group.47 Moreover, the cardiovascular benefits
were shown to be independent of renal function47,48 and
glucose levels,49 as well as consistent when adjusted for
baseline glycated hemoglobin (HbA1c) levels.
49,50
Building on results from the EMPA-REG OUTCOME trial, the
CANVAS study program (integrated data from 2 trials, CANVAS
[Canagliflozin Cardiovascular Assessment Study] and CANVAS-R
[Canagliflozin Cardiovascular Assessment Study - Renal]) inves-
tigated the SGLT-2 inhibitor canagliflozin in patients with T2D and
either established atherosclerotic disease (n=6656; 66%) or at
high risk for cardiovascular events (n=3486; 34%).51 Canagliflozin
significantly reduced the exploratory endpoint of hHF versus
placebo (3.2% ARR; 33% relative risk reduction) in both patient
subsets and also in patients with and without history of HF.51,52
The DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovas-
cular Events-Thrombolysis in Myocardial Infarction 58) trial,
published in November 2018, is the first CVOT to include hHF
or cardiovascular death as 1 of its primary end points. The
DECLARE-TIMI 58 trial investigated the effects of dapagliflozin
versus placebo in a broad population of patients (N=17 160)
with T2D who had either multiple cardiovascular risk factors
(59.4%) or established atherosclerotic disease (40.6%).53
Dapagliflozin met 1 of its primary end points of a statistically
significant reduction in hHF or cardiovascular death versus
placebo, which was driven by a lower rate in hHF.
Dapagliflozin was associated with an 0.8% ARR and 27%
relative risk reduction in hHF. The benefit in hHF was
consistent in patients with and without recognized atheroscle-
rotic disease and also in patients with and without a previous
history of HF.53 Recent subanalyses of the DECLARE-TIMI 58
trial have shown that reductions in hHF with dapagliflozin also
occurred both in patients with and without a previous MI and
both in patients with and without peripheral artery disease,
although those with previous MI and those with peripheral
artery disease had a greater ARR.54,55
A recent meta-analysis of the three CVOT analyses showed
that SGLT-2 inhibitors, as a class, reduced the risk of hHF by
31%, and again that this risk reduction was consistent in
patients with and without recognized atherosclerotic disease
(30% reduction in risk of hHF in both subgroups) and in
patients with and without a history of HF.56 Real-world
studies, such as CVD-REAL (Comparative Effectiveness of
Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors)
and the ongoing EMPRISE (Non-interventional Study on the
Effectiveness and Safety of Empagliflozin Compared With
DPP-4 Inhibitors in Patients With Type 2 Diabetes in the
United States) trial, have also demonstrated the positive
effects of SGLT-2 inhibitors on hHF prevention in patients with
T2D irrespective of atherosclerotic disease status, providing
consistent results in a practice-based setting.57-59
Safety of SGLT-2 Inhibitors
Current evidence from trials of SGLT-2 inhibitors in patientswith
T2D suggests these drugs are generally well tolerated. A
common side effect of SGLT-2 inhibitors is genital infections,
which typically manifest early during treatment expo-
sure.47,52,53,60 Infections can be prevented if appropriate
hygiene measures are taken, but should infection occur, it can
be effectively managed.60 Diabetic ketoacidosis can occur in
patients treated with SGLT-2 inhibitors, although cases are very
rare and mainly associated with the use of insulin.47,52,53,60
Current guidance suggests that, should symptoms of diabetic
ketoacidosis arise in patients receiving SGLT-2 inhibitors,
treatment should be discontinued immediately.61,62
In the CANVAS trial, although the overall incidence of lower
limb amputations was low, the frequency of these events was
significantly greater in patients treated with canagliflozin
versus placebo.52 Accordingly, European Medicines Agency
guidance highlights the need for caution when prescribing
SGLT-2 inhibitors in patients at high risk of amputation.63
Whether the increased risk of amputation observed in the
CANVAS trial is the result of a class effect across all SGLT-2
inhibitors is the subject of significant debate. Notably, neither
the EMPA-REG OUTCOME nor DECLARE-TIMI 58 trial showed
DOI: 10.1161/JAHA.119.013389 Journal of the American Heart Association 3
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an increase in the incidence of amputations with empagliflozin
and dapagliflozin, respectively, compared with placebo.47,53
Furthermore, a meta-analysis of the results from the CANVAS,
EMPA-REG OUTCOME, and DECLARE-TIMI 58 trials showed
significant heterogeneity among the 3 trials with respect to
amputations, suggesting that an increased risk of these events
was evident only in the CANVAS trial.56 Conversely, recent
registry data demonstrated an increased risk of amputation
with SGLT-2 inhibitors as compared with glucagon-like peptide-
1 agonists.64 Although the study was confounded by perform-
ing analyses for SGLT-2 inhibitors as a class, it is noteworthy
that the study reports the use of canagliflozin to be rare,
considering outcomes of the 3 major CVOTs concerning
amputations.
Data are also inconsistent with regard to risk of bone
fractures during SGLT-2 inhibitor treatment. Although the
Figure 1. Key unmet needs in the management of HF.5,6,32,33 ACE indicates angiotensin-converting
enzyme; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with
reduced ejection fraction; RAAS, renin-angiotensin-aldosterone system.
DOI: 10.1161/JAHA.119.013389 Journal of the American Heart Association 4
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incidence of fractures was significantly greater with canagli-
flozin versus placebo in the CANVAS trial, this finding was not
mirrored in the EMPA-REG OUTCOME, DECLARE-TIMI 58, and
CANVAS-R trials47,52,53 or in registry data.64
Further research is clearly required to ascertain whether
there is a genuine increased risk of amputations and fractures
associated with SGLT-2 inhibitor treatment and, if so, whether
it is applicable to all drugs in that class or specific to an
individual agent.
Can SGLT-2 Inhibitors Be Beneficial in the
Treatment of HF?
Results from current CVOTs show promise for SGLT-2
inhibitors in the prevention of HF in patients with T2D across
a spectrum of cardiovascular risk. Whether SGLT-2 inhibitors
can be beneficial in the treatment of HF remains to be
elucidated; efficacy in the prevention of HF does not
necessarily translate to efficacy in the treatment of HF—the
GISSI-HF (GISSI Heart Failure) and CORONA (Controlled
Rosuvastatin Multinational Trial in Heart Failure) trials exem-
plify this notion. Despite statins being the cornerstone
pharmacological intervention in the prevention of heart
disease, in both the GISSI-HF and CORONA trials, rosuvastatin
failed to show benefit in patients with chronic HF.65,66
However, there is rationale to suggest that SGLT-2 inhibitors
may be beneficial in the treatment of established HF in patients
with T2D. As previously discussed, a meta-analysis of EMPA-
REG OUTCOME, CANVAS, and DECLARE-TIMI 58 demon-
strated cardiovascular benefit with SGLT-2 inhibitors in
patients with and without a history of HF.56 Moreover,
subanalyses of the EMPA-REG OUTCOME and CANVAS trials
demonstrated that the ARR in hHF may be greater in patients
with a history of HF than in those without; that is, at least for
patients with high cardiovascular risk.67,68 Only a minority of
patients in the EMPA-REG OUTCOME, CANVAS, and DECLARE-
TIMI 58 trials had investigator-reported HF (10%), and no HF
phenotyping (by EF or natriuretic peptide levels) was initially
performed for these patients in the EMPA-REG OUTCOME and
CANVAS trials.53,68,69 The DECLARE-TIMI 58 trial collected
data on HF phenotype in patients with a history of HF (including
history and etiology of HF, baseline EF, and functional class). Of
the total 17 160 patients enrolled, 671 (4%) had an EF<45%
and were classified as HFrEF; 1316 (8%) had a history of HF
without a reduced EF (808 with recorded EF≥45% and 508
without a documented EF).70 Dapagliflozin reduced the primary
composite end point of cardiovascular death or hHF to a
greater extent in patients with HFrEF than in those without.70
This difference was driven by significant reductions in cardio-
vascular death in patients with HFrEF but not in those without;
all-cause mortality was also reduced in patients with HFrEF but
not in those without. Reductions in hHF were seen irrespective
of baseline EF. Of note, patients with reduced EF, in particular
an EF<30%, derived greater relative cardiovascular benefit than
those with a higher EF.70 It is also noteworthy that the
cardiovascular benefits in patients with HFrEF were seen in
patients previously treated with current evidence-based ther-
apies (eg, ACE inhibitors, b-blockers, ARBs).70
A subanalysis of the CANVAS trial retrospectively assessed
type of HF events in the study (HFrEF or HFpEF) using patients’
medical records data (reviewed by an original member of the
Adjudication Committee who was blinded to patient treatment
assignment). Of the 10 142 patients enrolled in the study, 101
had a first HF event considered as HFpEF (EF≥50%), 122 had a
first event considered HFrEF (EF<50%), and 61 had a first
event with unknown EF.71 The overall risk of HF events was
shown to be reduced with canagliflozin versus placebo. The
hazard ratio for HFrEF events was 0.69 (95% CI 0.48-1.00),
that for HFpEF events was 0.83 (95% CI 0.55-1.25), and that
for HF events with unknown EF was 0.54 (95% CI 0.32-0.89).
In the sensitivity analysis, where unknown EF events were
assumed to be HFpEF, the updated hazard ratio for HFpEF
events was 0.71 (95% CI 0.52-0.97), and if the unknown EF
events were assumed to be HFrEF events, the updated hazard
ratio for HFrEF events was 0.64 (95% CI 0.48-0.86). The
authors, therefore, concluded that canagliflozin reduced the
overall risk of HF events in patients with T2D and high
cardiovascular risk, with no clear difference in effects on
HFrEF versus HFpEF events.71 Unfortunately, EF at baseline
was not available in this study. It will be interesting to see
whether results from this subanalysis are reflected in ongoing
dedicated HFrEF and HFpEF trials of SGLT-2 inhibitors,
particularly the latter in view of the lack of available treatment
options for patients with HFpEF.
Accumulating mechanistic insights (Table) suggest that
SGLT-2 inhibitors may be valuable in the treatment of HF
regardless of diabetes mellitus status and EF. SGLT-2 inhibitors
may exert cardioprotective effects through several distinct
mechanisms, including (1) improvement in ventricular loading
conditions secondary to reductions in preload (mediated by
osmotic diuresis and natriuresis)72,73 and afterload (potentially
occurring via lowering of arterial pressure and stiffness);74,75
(2) provision of an alternative cardiac energy supply in the form
of cardiac ketones (specifically b-hydroxybutyrate);76,77 (3)
direct inhibition of the sodium/hydrogen (Na+/H) exchanger in
the myocardium,78 leading to reduction in or reversing of
cardiac injury, hypertrophy, fibrosis, remodeling, and systolic
dysfunction;79-81 (4) reduction in left ventricular mass and
improvement in diastolic function82,83 through inhibition of
cardiac fibrosis (a feature of HF);80,84,85 (5) improvement in
endothelial dysfunction;86,87 and (6) stimulation of increased
glucagon secretion,88,89 potentially improving cardiac perfor-
mance by either increasing cardiac index and fuel availability or
decreasing peripheral vascular resistance.90
DOI: 10.1161/JAHA.119.013389 Journal of the American Heart Association 5
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Renal Disease Adversely Impacts HF Outcomes,
and SGLT-2 Inhibitors May Offer Renal Protection
The recent CARMALINA trial highlights the deleterious effects
of renal dysfunction on HF outcomes in patients with T2D,
with or without prior history of HF. In the placebo group of the
trial, there was a 2.7-fold and a 4.2-fold higher risk of hHF in
patients with estimated glomerular filtration rate (eGFR)
<60 mL/min per 1.73 m2 and <30 mL/min per 1.73 m2,
respectively, compared with those with eGFR ≥60 mL/min
per 1.73 m2.95 Moreover, in the SAVOR-TIMI 53 (Saxagliptin
Assessment of Vascular Outcomes Recorded in Patients With
Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53)
trial, worsening renal function was associated with a higher
risk of both hHF and atherothrombotic events in patients with
T2D during a median follow-up of 2 years.96 Notably, with
worsening renal function, risk of hHF was shown to be much
higher than risk of atherothrombotic events. Whether
improvement in renal function translates to cardiovascular
benefit in patients with HF remains to be seen. However, it has
been postulated that the kidney protection and natriuretic
effects induced by SGLT-2 inhibitors may account for the
reductions in hHF in the EMPA-REG OUTCOME, CANVAS, and
DECLARE-TIMI 58 trials. Moreover, the reduction in hHF in
these trials was greater in patients with worse baseline renal
function; a 40% reduction in hHF was observed in patients with
eGFR <60 mL/min per 1.73 m2 compared with 31% and 12%
reductions in patients with eGFR ≥60 to <90 mL/min per
1.73 m2 and eGFR ≥90 mL/min per 1.73 m2, respectively.56
Interestingly, although the magnitude of benefit from SGLT-2
inhibition on hHF was greater (P value for interaction=0.0073)
in patients with more severe renal disease at baseline, the
benefit on progression of renal disease was lower in these
patients (P value for interaction=0.0258). Most recently,
results from the CREDENCE (Canagliflozin and Renal Events in
Table. Overview of Potential Mechanisms of Improved
Cardiac Function With SGLT-2 Inhibitors72-94
Potential Mechanisms
1. Stimulation of natriuresis
2. Stimulation of osmotic diuresis
3. Cardiomyocyte Na+/H exchanger inhibition
4. Increased myocardial energetics (via altered
myocardial substrate metabolism)
5. Reduction in left ventricular mass
6. Improved systolic and diastolic function
7. Improved cardiac filling conditions secondary
to reductions in preload and afterload
8. Increased circulating proangiogenic progenitor cells
9. Increased erythropoietin
10. Improved endothelial function
11. Reduction in myocardial CaM kinase II activity
12. Improved myocardial autophagy
13. Inhibition of cardiac fibrosis
14. Increased cardiac output, HR, O2 consumption, coronary blood flow
mediated by increased levels of circulating glucagon
CaM indicates Ca2+/calmodulin-dependent protein; HR, heart rate; SGLT-2, sodium-
glucose cotransporter-2.
Figure 2. Mechanistic rationale for investigating SGLT-2 inhibitors in HF beyond T2D. CV indicates
cardiovascular; HF, heart failure; SGLT-2, sodium-glucose cotransporter-2; T2D, type 2 diabetes mellitus.
DOI: 10.1161/JAHA.119.013389 Journal of the American Heart Association 6
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Diabetes with Established Nephropathy Clinical Evaluation)
trial, which investigated canagliflozin versus placebo on renal
outcomes in 4401 patients with T2D and albuminuric CKD,
support the notion that renal protection and cardiovascular
benefit induced by SGLT-2 inhibitors may be interlinked. The
trial was prematurely stopped based on achievement of the
prespecified efficacy criteria for the primary composite end
point of time to first occurrence of end-stage kidney disease,
doubling of serum creatinine, or cardiovascular/renal death.
Canagliflozin recipients also benefited from significant reduc-
tions in secondary end points of cardiovascular death or hHF
and of hHF versus those on placebo. As in the DECLARE-TIMI
58 trial, cardiovascular death was not reduced in the
CREDENCE trial, suggesting that the reduction in the
composite of cardiovascular death or hHF was driven by a
reduction in hHF.97
SGLT-2 Inhibitors May Have Beneficial Effects in
Patients Without Diabetes Mellitus
Patients with HF, regardless of EF, have sodium and fluid
retention as well as coronary, myocardial, and systemic
endothelial dysfunction, even in the absence of overt diabetes
mellitus. As the natriuretic (most notably), glucosuric, and
metabolic effects of SGLT-2 inhibitors have been demon-
strated in patients with and without diabetes mellitus,98-100 it
has been postulated that SGLT-2 inhibitors may benefit
patients with HF regardless of diabetes mellitus status
(Figure 2). This has been demonstrated in several preclinical
studies.85,101-103 In a preclinical model of HF, empagliflozin
treatment (or gene knockout simulation of SGLT-2 inhibition)
improved cardiac function.101 In preclinical models of MI,
dapagliflozin has demonstrated attenuation of cardiac fibrosis,
and empagliflozin has been shown to improve cardiac function
and remodeling.85,102 In other experimental models of HF
without diabetes mellitus, empagliflozin prevented worsening
of cardiac function.103
Unanswered Questions and Future Direction
Outcomes of several ongoing prospective studies of SGLT-2
inhibitors in HF (Figure 3) are needed to fully evaluate the
therapeutic potential of SGLT-2 inhibitors in HF, with and
without diabetes mellitus and with preserved or reduced EF.
Of particular interest are the larger upcoming dapagliflozin
and empagliflozin outcome trials (N>2000) in both HFrEF
(DAPA-HF [Dapagliflozin And Prevention of Adverse-out-
comes in Heart Failure] and EMPEROR-Reduced [Empagli-
flozin Outcome Trial in Patients with Chronic Heart Failure
with Reduced Ejection Fraction]) and HFpEF (DELIVER
[Dapagliflozin Evaluation to Improve the Lives of Patients
with Preserved Ejection Fraction Heart Failure] and
EMPEROR-Preserved [Empagliflozin Outcome Trial in Patients
with Chronic Heart Failure with Preserved Ejection Fraction]),
which are due to read out from 2019 onward (Figure 3) and
may help establish whether there is a role for these SGLT-2
inhibitors in HF independent of diabetes mellitus.
A recent randomized trial of empagliflozin versus placebo
(EMPA-HEART [Effects of Empagliflozin on Cardiac Structure,
Function, and Circulating Biomarkers in Patients With Type 2
Diabetes]) in patients with T2D showed that empagliflozin
treatment resulted in early and significant reduction in left
ventricular mass regression, as detected by cardiac magnetic
resonance imaging, which suggests reverse cardiac remodel-
ing may be a possible contributor to the cardioprotective
effects of SGLT-2 inhibitors.115 By investigating the effects of
SGLT-2 inhibitors on HF-specific biomarkers, hemodynamics,
and cardiac structure/function, the PRESERVED-HF (Effects
of Dapagliflozin on Biomarkers, Symptoms and Functional
Status in Patients with Preserved Ejection Fraction Heart
Failure; primary end point: change from baseline in N-terminal
prohormone of brain natriuretic peptide [NTproBNP] at weeks
6 and 12 in patients with HFpEF), DEFINE-HF (Dapagliflozin
Effect on Symptoms and Biomarkers in Patients with Heart
Failure; primary end point: change in NTproBNP at weeks 6
and 12 in patients with HFrEF), and EMBRACE-HF (Empagli-
flozin Evaluation by Measuring Impact on Hemodynamics in
Patients with Heart Failure; primary end point: change in
pulmonary artery diastolic pressure from baseline to end of
treatment with empagliflozin versus placebo) trials will help to
further elucidate the potential beneficial effects of SGLT-2
inhibitors on cardiovascular outcomes in patients with and
without T2D. Sotagliflozin, currently being investigated in the
SOLOIST-WHF(Effect of Sotagliflozin on Cardiovascular Events
in Patients with Type 2 Diabetes Post Worsening Heart
Failure) trial, is a dual SGLT-1/SGLT-2 antagonist. Accord-
ingly, the biology of this agent differs slightly from the 3 SGLT-
2 inhibitors prospectively studied to date. Thus, it is possible
sotagliflozin may exhibit some drug-specific effects, and it will
be interesting to see whether the safety and efficacy impacts
of this agent replicate those observed with SGLT-2 inhibitors.
In addition to the recently published CREDENCE trial,
several other trials dedicated to investigating renal and
cardiovascular outcomes with SGLT inhibitors, which may
shed light on the extent to which the renal effects of SGLT-2
inhibitors contribute to the cardiovascular benefits these
drugs appear to provide, are ongoing. These trials include, but
are not restricted to, DAPA-CKD (A Study to Evaluate the
Effect of Dapagliflozin on Renal Outcomes and Cardiovascular
Mortality in Patients with Chronic Kidney Disease; primary
composite end point: time to first occurrence of ≥50%
sustained decline in eGFR, reaching end-stage renal disease
or cardiovascular/renal death) and EMPA-KIDNEY (A Multi-
centre International Randomized Parallel Group Double-blind
DOI: 10.1161/JAHA.119.013389 Journal of the American Heart Association 7
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Placebo-controlled Clinical Trial of Empagliflozin Once Daily to
Assess Cardio-renal Outcomes in Patients with Chronic
Kidney Disease; primary composite end point: time to first
occurrence of kidney disease progression [defined as end-
stage kidney disease, a sustained decline in eGFR to <10 mL/
min per 1.73 m2, renal death, or a sustained decline of ≥40%
in eGFR from randomization] or cardiovascular/renal death).
Conclusion
HF is a highly debilitating condition affecting millions of
individuals worldwide for which there remains substantial
unmet needs for (1) prevention of HF by early recognition and
treatment of individuals at risk; (2) improved adherence to
treatment guidelines with respect to up-titration of evidence-
Figure 3. Ongoing trials of SGLT-2 inhibitors in HF.104-114 *Dual SGLT-1/SGLT-2 receptor antagonist. EF
indicates ejection fraction; LPLV, last patient last visit; SGLT-2, sodium-glucose co-transporter-2; T2D, type
2 diabetes mellitus.
DOI: 10.1161/JAHA.119.013389 Journal of the American Heart Association 8
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based therapies among patients with established disease;
and (3) additional effective and well-tolerated therapeutic
options, particularly in patients with HFpEF, as well as those
with cardiorenal disease. SGLT-2 inhibitors have emerged as
a potential effective class of drug for the prevention of HF in
patients with T2D. Mounting mechanistic evidence indicates
that these drugs may also induce combined cardiac and renal
beneficial effects and hold promise for the treatment of HF in
patients with and without diabetes mellitus, as well as in both
HFpEF and HFrEF. Whether this promise translates to clinical
efficacy remains to be seen, but results of highly anticipated
ongoing trials may help to provide the answer to this
question.
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